A first-in-class inhibitor of HSP110 to potentiate XPO1-targeted therapy in primary mediastinal B-cell lymphoma and classical Hodgkin lymphomaManon Durand, Gaëtan Jégo|Journal of Experimental & Clinical Cancer Research|2024Cited by 7